BACKGROUND: Obesity-associated @entity101 is difficult to treat and puts @entity1 at a substantially increased risk of cardiovascular events. @entity7056 has previously been shown to effectively lower blood pressure (BP) in high-risk groups including @entity1 with @entity6 or @entity8 , and may therefore also be suitable for the treatment of @entity28 -associated @entity101 . In this study we aimed to: (a) assess the efficacy and tolerability of @entity7056 alone and in combination with @entity918 in @entity1 with @entity28 -associated mild-to-moderate @entity101 ; and (b) investigate @entity1 -associated determinants of poor BP control in this @entity1 group. @entity1 AND METHODS: This was a 3-month, prospective, open-label, multicentre, phase IV study in 72 479 @entity101 @entity1 in 6989 general practices across Germany. Main outcome measures were @entity551 (primary parameter of effectiveness) and BP response rates after 3 months, as well as adverse events (AEs). Independent predictors of poor control were identified in a multivariate proportional odds model. RESULTS: All of the @entity1 were Caucasian, 50.5% were females, mean age was 62.1 +/- 11.1 years, mean bodyweight was 88.6 +/- 15.4kg, and mean body mass index (BMI) was 30.7 +/- 4.8 kg/m(2). Almost all the @entity1 were overweight or @entity28 (92.3%). From a baseline value of 162/94mm Hg, systolic and diastolic BP were reduced by a mean of -23/-12mm Hg after 3 months. 66.1% of the @entity1 were responders (reduction of diastolic BP >/=10mm Hg), and 48.0% achieved BP normalisation (i.e. <140/90mm Hg). 79% of @entity1 met their individual treatment goals as defined by the treating physician (mean 135/80mm Hg). AEs were reported in only 322 @entity1 (0.4%). Factors requiring special attention in @entity1 not achieving BP control were age (>55 years), high BMI category (>25 kg/m(2)), and increased waist circumference. CONCLUSION: Treatment with @entity7056 (+/- @entity918 ) appeared to be effective and well tolerated in the study population of @entity1 with @entity28 - associated @entity101 . Easily recognisable characteristics allow physicians to identify @entity1 whose BP is likely to be difficult to control.

Antihypertensive effect of @entity7056 and predictors of response in XXXX -associated @entity101 : a prospective, open-label study.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS'] @entity8 :: ('MESH:D007674', 'Disease') :: ['nephropathy'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension', 'hypertensive'] @entity6 :: ('MESH:D003920', 'Disease') :: ['type 2 diabetes mellitus'] @entity28 :: ('MESH:D009765', 'Disease') :: ['obese', 'obesity'] @entity918 :: ('MESH:D006852', 'Chemical') :: ['hydrochlorothiazide'] @entity7056 :: ('MESH:C081309', 'Chemical') :: ['irbesartan', 'Irbesartan'] @entity551 :: ('MESH:D007022', 'Disease') :: ['BP reduction']
@entity28 :: (MESH:D009765,Disease) :: ['obesity']
